A Phase II Trial to Assess the Efficacy of Efavirenz in Metastatic Patients With Androgen-independent Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Efavirenz (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms FAVE
- 10 Jun 2017 Biomarkers information updated
- 29 Jun 2012 Bristol-Myers Squibb added as associations as reported by European Clinical Trials Database.
- 17 Mar 2012 Planned end date changed from 1 Dec 2009 to 4 Aug 2011 as reported by European Clinical Trials Database.